IQV files 8-K — Item 2.02 Results of Operations

IQVIA Holdings Inc. (IQV) filed an 8-K disclosing Item 2.02 (Results of Operations and Financial Condition) with the SEC on 2026-05-05 at 07:03:40, per official EDGAR records.

What Was Filed

The $26.8B market-cap healthcare diagnostics and research firm submitted the filing, which links directly to its Q1 2026 earnings press release at the provided EDGAR URL. Per SEC plain-language rules, Item 2.02 covers public announcements of quarterly operating and financial performance, and no additional SEC disclosure items were included in this filing.

The Disclosure Content

Item 2.02 filings for large-cap life sciences analytics and contract research firms typically include top-line revenue, adjusted and GAAP earnings per share (EPS), segment performance highlights, and often near-term or full-year forward guidance. This filing confirms IQV released preliminary Q1 2026 results ahead of its formal 10-Q quarterly submission, aligning with standard S&P 500 earnings timeline practices.

Cross-Referenced Prior Signals

This earnings filing aligns with four recent data points from the provided research context:

1. Earnings Performance: Reported Q1 2026 revenue hit $4.151B, beating consensus estimates of $4.099969B by approximately $51 million, following three consecutive quarters of revenue beats in 2025 and Q4 2025. Reported GAAP/adjusted EPS was not disclosed, though it missed the consensus estimate of $2.83.

2. Insider Transactions: Eight independent directors received 1,571 stock awards each on 2026-04-27, with no cash exchange required, exactly one week before this 8-K filing.

3. Institutional Ownership: As of 2025-12-31, IQV had 1,151 institutional holders (a 113-quarter-over-quarter increase), with 94.5% of its float held by institutional investors, including 223 new positions and 622 increased positions in the final quarter of 2025.

4. Analyst Ratings: As of 2026-04-01, the consensus analyst split was 4 Strong Buy, 17 Buy, 3 Hold, with no Sell or Strong Sell ratings, a slight decline from the 5 Strong Buy ratings tracked in March 2026.

What This Filing Does NOT Tell Us

1. Segmental revenue breakdown: The filing does not disclose performance for IQV’s three core operating segments, which would clarify which division drove the Q1 top-line beat.

2. Actual reported EPS value: Only the consensus estimate and actual-versus-estimate gap was referenced, not the raw reported earnings per share figure.

3. Forward guidance details: While common in Item 2.02 filings, the linked press release has not been publicly summarized to confirm whether 2026 full-year or Q2 2026 financial targets were disclosed.